Trial Profile
A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-659/TEZ/IVA Triple Combination Therapy in Cystic Fibrosis Subjects 6 Through 11 Years of Age
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2020
Price :
$35
*
At a glance
- Drugs Ivacaftor (Primary) ; Ivacaftor/tezacaftor/VX-659 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Sponsors Vertex Pharmaceuticals
- 21 Aug 2019 Status changed from recruiting to discontinued.
- 29 Aug 2018 Status changed from not yet recruiting to recruiting.
- 23 Aug 2018 New trial record